Ana Contreras

Dr. Ana Contreras

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Neuroscience
Verified
Journal Article
Closed access
VNVíctor Naranjo
Víctor Naranjo
ACAna Contreras
Ana Contreras
BMBeatriz Merino
Beatriz Merino
APAdrián Plaza
Adrián Plaza
MLMaría P. Lorenzo
María P. Lorenzo
Cano VictoriaCano Victoria
Cano Victoria

Verified
Journal Article
Open access
PDF file
AFAgueda Ferrer-Donato
Agueda Ferrer-Donato
ACAna Contreras
Ana Contreras
LFLaura M Frago
Laura M Frago
JCJulie Ann Chowen
Julie Ann Chowen
CFCarmen M. Fernandez-Martos
Carmen M. Fernandez-Martos
Leptin has been suggested to play a role in amyotrophic lateral sclerosis (ALS), a fatal progressive neurodegenerative disease. This adipokine has previously been shown to be associated with a lower risk of ALS and to confer a survival advantage in ALS patients. However, the role of leptin in the progression of ALS is unknown. Indeed, our understanding of the mechanisms underlying leptin’s effects in the pathogenesis of ALS is very limited, and it is fundamental to determine whether alterations in leptin’s actions take place in this neurodegenerative disease. To characterize the association between leptin signaling and the clinical course of ALS, we assessed the mRNA and protein expression profiles of leptin, the long-form of the leptin receptor (Ob-Rb), and leptin-related signaling pathways at two different stages of the disease (onset and end-stage) in TDP-43A315T mice compared to age-matched WT littermates. In addition, at selected time-points, an immunoassay analysis was conducted to characterize plasma levels of total ghrelin, the adipokines resistin and leptin, and metabolic proteins (plasminogen activator inhibitor type 1 (PAI-1), gastric inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), insulin and glucagon) in TDP-43A315T mice compared to WT controls. Our results indicate alterations in leptin signaling in the spinal cord and the hypothalamus on the backdrop of TDP-43-induced deficits in mice, providing new evidence about the pathways that could link leptin signaling to ALS.

16 September 2023 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
RJRaquel Jiménez-Herrera
Raquel Jiménez-Herrera
ACAna Contreras
Ana Contreras
SDSouhail Djebari
Souhail Djebari
JMJaime Mulero-Franco
Jaime Mulero-Franco
GIGuillermo Iborra-Lázaro
Guillermo Iborra-Lázaro
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
Background: The amyloid-β (Aβ) cascade is one of the most studied theories linked to AD. In multiple models, Aβ accumulation and dyshomeostasis have shown a key role in AD onset, leading to excitatory/inhibitory imbalance, the impairments of synaptic plasticity and oscillatory activity, and memory deficits. Despite the higher prevalence of Alzheimer’s disease (AD) in women compared to men, the possible sex difference is scarcely explored and the information from amyloidosis transgenic mice models is contradictory. Thus, given the lack of data regarding the early stages of amyloidosis in female mice, the aim of this study was to systematically characterize the effect of an intracerebroventricular (icv.) injection of Aβ1–42 on hippocampal-dependent memory, and on associated activity-dependent synaptic plasticity in the hippocampal CA1–CA3 synapse, in both male and female mice. Methods: To do so, we evaluated long term potentiation (LTP) with ex vivo electrophysiological recordings as well as encoding and retrieval of spatial (working, short- and long-term) and exploratory habituation memories using Barnes maze and object location, or open field habituation tasks, respectively. Results: Aβ1–42 administration impaired all forms of memory evaluated in this work, regardless of sex. This effect was displayed in a long-lasting manner (up to 17 days post-injection). LTP was inhibited at a postsynaptic level, both in males and females, and a long-term depression (LTD) was induced for the same prolonged period, which could underlie memory deficits. Conclusions: In conclusion, our results provide further evidence on the shifting of LTP/LTD threshold due to a single icv. Aβ1–42 injection, which underly cognitive deficits in the early stages of AD. These long-lasting cognitive and functional alterations in males and females validate this model for the study of early amyloidosis in both sexes, thus offering a solid alternative to the inconsistence of amyloidosis transgenic mice models.

19 July 2023 in Neuropharmacology
Verified
Journal Article
Closed access
ACAna Contreras
Ana Contreras
SDSouhail Djebari
Souhail Djebari
STSara Temprano-Carazo
Sara Temprano-Carazo
AMAlejandro Múnera
Alejandro Múnera
AGAgnès Gruart
Agnès Gruart
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez

Verified
Journal Article
Open access
PDF file
STSara Temprano-Carazo
Sara Temprano-Carazo
ACAna Contreras
Ana Contreras
Carlos SauraCarlos Saura
Carlos Saura
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
G-protein-gated inwardly rectifying potassium (GIRK) channels are critical determinants of neuronal excitability. They have been proposed as potential targets to restore excitatory/inhibitory balance in acute amyloidosis models, where hyperexcitability is a hallmark. However, the role of GIRK signaling in transgenic mice models of Alzheimer’s disease (AD) is largely unknown. Here, we study whether progressive amyloid-β (Aβ) accumulation in the hippocampus during aging alters GIRK channel expression in mutant β-amyloid precursor protein (APPSw,Ind J9) transgenic AD mice. Additionally, we examine the impact of spatial memory training in a hippocampal-dependent task, on protein expression of GIRK subunits and Regulator of G-protein signaling 7 (RGS7) in the hippocampus of APPSw,Ind J9 mice. Firstly, we found a reduction in GIRK2 expression (the main neuronal GIRK channels subunit) in the hippocampus of 6-month-old APPSw,Ind J9 mice. Moreover, we found an aging effect on GIRK2 and GIRK3 subunits in both wild type (WT) and APPSw,Ind J9 mice. Finally, when 6-month-old animals were challenged to a spatial memory training, GIRK2 expression in the APPSw,Ind J9 mice were normalized to WT levels. Together, our results support the evidence that GIRK2 could account for the excitatory/inhibitory neurotransmission imbalance found in AD models, and training in a cognitive hippocampal dependent task may have therapeutic benefits of reversing this effect and lessen early AD deficits.

13 June 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JMJaime Mulero-Franco
Jaime Mulero-Franco
RJRaquel Jimenez-Herrera
Raquel Jimenez-Herrera
ACAna Contreras
Ana Contreras
SDSouhail Djebari
Souhail Djebari
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
Selective pharmacological activation of G protein-gated inwardly rectifying K⁺ (GIRK) channels -a key physiological determinant of neuronal excitability control- has proven highly effective in counteracting amyloid-β oligomer (oAβ)-induced hyperexcitability and hippocampal dysfunction in early Alzheimer's disease (AD). However, GIRK gain-of-function in healthy animals disrupts learning, memory and underlying synaptic plasticity, greatly limiting its therapeutic potential in preclinical asymptomatic AD patients. Therefore, GIRK-based pharmacological treatment needs further investigation to overcome these limitations. Here we tested two doses of a novel, more potent, and neuronal selective GIRK activator, VU0810464, in healthy and intracerebroventricular (icv.) oAβ1-42-induced AD-like male and female mice. Both doses normalized: 1) at the synaptic level, CA3-CA1 long-term synaptic potentiation (LTP) in hippocampal slices, and 2) at the behavioral level, object location memory (OLM), a hippocampal-dependent spatial contextual recognition memory task. However, in healthy mice, while a low VU0810464 dose had no significant effect on hippocampal LTP and OLM, the higher dose impaired both processes. Importantly, these effects were consistent across sexes, as no sex differences were observed in any condition. Finally, VU0810464 reduced oAβ-induced hippocampal hyperexcitability, providing direct functional evidence of a mechanistic link between GIRK activation and restoration of network excitability. Our results suggest that the precise tuning of neural excitability with low dosing of VU0810464 might be a promising strategy to safely treat and prevent hippocampal overexcitation and upstreaming memory deficits in early preclinical asymptomatic phases of AD.